These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 27035363)
1. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Hannan R; Tumati V; Xie XJ; Cho LC; Kavanagh BD; Brindle J; Raben D; Nanda A; Cooley S; Kim DWN; Pistenmaa D; Lotan Y; Timmerman R Eur J Cancer; 2016 May; 59():142-151. PubMed ID: 27035363 [TBL] [Abstract][Full Text] [Related]
2. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints. Meier RM; Bloch DA; Cotrutz C; Beckman AC; Henning GT; Woodhouse SA; Williamson SK; Mohideen N; Dombrowski JJ; Hong RL; Brachman DG; Linson PW; Kaplan ID Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):296-303. PubMed ID: 30191864 [TBL] [Abstract][Full Text] [Related]
3. High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. D'Agostino G; Franzese C; De Rose F; Franceschini D; Comito T; Villa E; Alongi F; Liardo R; Tomatis S; Navarria P; Mancosu P; Reggiori G; Cozzi L; Scorsetti M Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e173-e178. PubMed ID: 27389021 [TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)). Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer. Potters L; Rana Z; Lee L; Cox BW Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):334-342. PubMed ID: 30721721 [TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079 [TBL] [Abstract][Full Text] [Related]
7. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity. Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782 [TBL] [Abstract][Full Text] [Related]
8. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer. Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713 [TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695 [TBL] [Abstract][Full Text] [Related]
10. Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer. Moore A; Kollmeier MA; McBride SM; Toumbacaris N; Zhang Z; Lacy-Elsayegh A; Dreyfuss A; Grossman CE; Gorovets D; Zelefsky MJ Eur Urol Oncol; 2024 Aug; 7(4):812-820. PubMed ID: 37949730 [TBL] [Abstract][Full Text] [Related]
11. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer. Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199 [TBL] [Abstract][Full Text] [Related]
12. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509 [TBL] [Abstract][Full Text] [Related]
13. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979 [TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study. Alayed Y; Loblaw A; Chu W; Al-Hanaqta M; Chiang A; Jain S; Chung H; Vesprini D; Morton G; Ravi A; Davidson M; Deabreu A; Mamedov A; Zhang L; Erler D; Cheung P Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1066-1073. PubMed ID: 31002941 [TBL] [Abstract][Full Text] [Related]
15. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes. Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102 [TBL] [Abstract][Full Text] [Related]
17. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes. Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511 [TBL] [Abstract][Full Text] [Related]
18. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. van As N; Griffin C; Tree A; Patel J; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Camilleri P; Kancherla K; Frew J; Chan A; Naismith O; Armstrong J; Staffurth J; Martin A; Dayes I; Wells P; Price D; Williamson E; Pugh J; Manning G; Brown S; Burnett S; Hall E N Engl J Med; 2024 Oct; 391(15):1413-1425. PubMed ID: 39413377 [TBL] [Abstract][Full Text] [Related]
19. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer. Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838 [TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Katz AJ; Santoro M; Diblasio F; Ashley R Radiat Oncol; 2013 May; 8():118. PubMed ID: 23668632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]